Litcius/Paper detail

Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality

Lawrence Liu, Alicia Yn, Feng Gao, Marissa Olson, Mallory Crain, Ramzi Abboud, Peter Westervelt, Camille N. Abboud, Ravi Vij, Keith Stockerl‐Goldstein, Iskra Pusic, Amanda F. Cashen, Mark A. Schroeder

2022Transplantation and Cellular Therapy41 citationsDOI

Topics & Concepts

MedicineHazard ratioInternal medicineDiscontinuationIncidence (geometry)Confidence intervalTransplantationCumulative incidenceRetrospective cohort studyCytomegalovirusPrednisoneImmunologyHuman immunodeficiency virus (HIV)HerpesviridaeViral diseasePhysicsOpticsCytomegalovirus and herpesvirus researchHerpesvirus Infections and TreatmentsParvovirus B19 Infection Studies
Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality | Litcius